Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG Treatment.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Scilipoti Pietro, Longoni Mattia, de Angelis Mario, Zaurito Paolo, Ślusarczyk Aleksander, Soria Francesco, Pradere Benjamin, Krajewski Wojciech, D'Andrea David, Mari Andrea, Giudice Francesco Del, Pichler Renate, Subiela José Daniel, Marcq Gautier, Gallioli Andrea, Afferi Luca, Mastroianni Riccardo, Simone Giuseppe, Albisinni Simone, Mertens Laura S, Laukhtina Ekaterina, Oberneder Katharina, Rodríguez Elena José Luis, Aranda Javier, Puentedura Alfonso Lafuente, Velasco Jorge Caño, Contieri Roberto, Hurle Rodolfo, Mori Keiichiro, Radziszewski Piotr, Shariat Shahrokh F, Gontero Paolo, Necchi Andrea, Rouprêt Morgan, Montorsi Francesco, Salonia Andrea, Briganti Alberto, Moschini Marco, European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group
Аннотация
METHODS: We analyzed data from a multicenter European database (2010-2024) for 1558 patients diagnosed with IR- or HiR-NMIBC who underwent BCG treatment and received at least five BCG instillations. Adequate BCG was defined as at least five of six induction instillations and two of three maintenance doses, or two of six doses of a reinduction course. A 3-mo landmark analysis was conducted. Recurrence-free survival (RFS), high-grade RFS (HG-RFS), progression-free survival (PFS), and overall survival (OS) were estimated using inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier curves and IPTW-adjusted multivariable Cox regression models. Cancer-specific mortality (CSM) was assessed via cumulative incidence curves and Fine-Gray competing-risks regression analysis.
KEY FINDINGS AND LIMITATIONS: The cohort included 606 IR-NMIBC (39%), 840 HiR-NMIBC (54%), and 112 very HiR (VHR)-NMIBC (7.1%) cases. Adequate BCG was administered to 1226 patients (78%). Among 1239 patients (80%) with documented treatment termination reasons, 503 (41%) completed guideline-recommended treatment and 150 (12%) discontinued because of BCG intolerance. Over median follow-up of 37 mo, adequate BCG was associated with higher IPTW-adjusted 5-yr RFS (72% vs 52%; hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.31-0.85; p < 0.001), HG-RFS (83% vs 68%; HR 0.43, 95% CI 0.32-0.58; p < 0.001), PFS (92% vs 85%; HR 0.47, 95% CI 0.30-0.74; p = 0.001), and OS (88% vs 71%; HR 0.52, 95% CI 0.37-0.74; p = 0.001). CSM rates were comparable between the groups (3% vs 4.9%; p = 0.3).
CONCLUSIONS AND CLINICAL IMPLICATIONS: Adequate BCG, as defined by the International Bladder Cancer Group (IBCG), was associated with significantly better RFS, PFS, and OS. These findings support use of the IBCG definition as a standardized benchmark for BCG exposure. However, further prospective validation to confirm causality is needed.